MC2010A1 - Pyrroles substitues - Google Patents

Pyrroles substitues

Info

Publication number
MC2010A1
MC2010A1 MC892032A MC2032A MC2010A1 MC 2010 A1 MC2010 A1 MC 2010A1 MC 892032 A MC892032 A MC 892032A MC 2032 A MC2032 A MC 2032A MC 2010 A1 MC2010 A1 MC 2010A1
Authority
MC
Monaco
Prior art keywords
substituted pyrroles
pyrroles
substituted
Prior art date
Application number
MC892032A
Other languages
English (en)
Inventor
David Davis Peter
Huw Hill Christopher
Lawton Geoffrey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803048A external-priority patent/GB8803048D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC2010A1 publication Critical patent/MC2010A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
MC892032A 1988-02-10 1989-02-06 Pyrroles substitues MC2010A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803048A GB8803048D0 (en) 1988-02-10 1988-02-10 Substituted pyrroles
GB888827565A GB8827565D0 (en) 1988-02-10 1988-11-25 Substituted pyrroles

Publications (1)

Publication Number Publication Date
MC2010A1 true MC2010A1 (fr) 1990-02-16

Family

ID=26293462

Family Applications (1)

Application Number Title Priority Date Filing Date
MC892032A MC2010A1 (fr) 1988-02-10 1989-02-06 Pyrroles substitues

Country Status (22)

Country Link
US (1) US5057614A (fr)
EP (1) EP0328026B1 (fr)
JP (1) JPH0730071B2 (fr)
AU (1) AU623630B2 (fr)
CA (1) CA1320194C (fr)
CZ (1) CZ280738B6 (fr)
DE (1) DE58904168D1 (fr)
DK (1) DK171891B1 (fr)
DZ (1) DZ1323A1 (fr)
ES (1) ES2054890T3 (fr)
FI (1) FI96861C (fr)
HU (1) HU201054B (fr)
IE (1) IE63489B1 (fr)
IL (1) IL89167A (fr)
IS (1) IS1941B (fr)
MC (1) MC2010A1 (fr)
NO (1) NO172540C (fr)
NZ (1) NZ227850A (fr)
PH (1) PH25185A (fr)
PT (1) PT89661B (fr)
SK (1) SK278989B6 (fr)
YU (1) YU47101B (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
CA2015996C (fr) * 1989-05-05 2001-08-28 Hartmut Osswald Derives de bis-(1h-indole-3-yl)-maleinimide et leur utilisation comme produits pharmaceutiques
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (fr) * 1990-08-07 2002-02-26 Peter D. Davis Pyrroles substitues
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (ja) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド 抗ウイルス活性を有するインドール誘導体
US5290777A (en) * 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
TW270114B (fr) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
PT657458E (pt) * 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (fr) * 1993-12-23 2010-01-27 Eli Lilly And Company Inhibiteurs de la protéine-kinase c
AU2771395A (en) * 1994-06-14 1996-01-05 Sloan-Kettering Institute For Cancer Research Ceramide-activated protein kinase and methods of use of effectors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
EP0695755B1 (fr) * 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
WO1997009339A1 (fr) * 1995-09-05 1997-03-13 Banyu Pharmaceutical Co., Ltd. Derives antitumoraux d'indolopyrrolocarbazole
YU49315B (sh) * 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
BR9710706A (pt) 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
EP0825190A1 (fr) * 1996-08-23 1998-02-25 Eli Lilly And Company Synthèse de bisindolylmaléimides
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ES2212814T3 (es) * 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. Uso de compuestos y composiciones antiinflamatorias neurogenicas.
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
US6133452A (en) * 1997-08-22 2000-10-17 Eli Lilly And Company Synthesis of bisindolylmalimides
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
BR9908882A (pt) * 1998-03-17 2000-11-21 Hoffmann La Roche Bisindolimaleimidas substituìdas para a inibição de proliferação de célula
SE9802538D0 (sv) * 1998-07-13 1998-07-13 Astra Ab New pharmaceutically active compounds
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
AU6111699A (en) * 1998-10-08 2000-05-01 Smithkline Beecham Plc Novel method and compounds
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
ES2208310T3 (es) * 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
WO2001013916A1 (fr) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Medicaments inhibant la mort cellulaire
US6559164B1 (en) 1999-10-12 2003-05-06 Hoffmann-La Roche Inc. Substituted pyrroles suitable for continuous infusion
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
CA2308994A1 (fr) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Composes neuroprotecteurs
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6353007B1 (en) * 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
HUP0301431A2 (hu) 2000-07-27 2003-08-28 F. Hoffmann-La Roche Ag. 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) * 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
KR20080014934A (ko) * 2000-11-07 2008-02-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
PT1362047E (pt) * 2000-12-08 2006-09-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituidos com indazolilo como inibidores de cinase
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
WO2002102373A1 (fr) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Procede d'administration d'un agent destine a la therapie du cancer
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
MXPA04004026A (es) * 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
KR100974770B1 (ko) * 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
JP2005530707A (ja) * 2002-03-08 2005-10-13 イーライ・リリー・アンド・カンパニー キナーゼ阻害物質
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP1900738A3 (fr) * 2002-05-08 2008-04-09 Janssen Pharmaceutica, N.V. Inhibiteurs substitués de la pyrroline kinase
AU2003225295A1 (en) 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
CA2488602A1 (fr) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Pyrrolines substitues en tant qu'inhibiteurs de kinase
CA2488798A1 (fr) * 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Pyrrolines substituees en tant qu'inhibiteurs de kinase
CA2393720C (fr) * 2002-07-12 2010-09-14 Eli Lilly And Company Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin
US6800655B2 (en) * 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
GB0303319D0 (en) * 2003-02-13 2003-03-19 Novartis Ag Organic compounds
WO2004094422A1 (fr) * 2003-03-27 2004-11-04 Janssen Pharmaceutica N.V. Pyrrolines substitues inhibiteurs de kinase
AU2004251178A1 (en) * 2003-06-13 2005-01-06 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
CN100536850C (zh) 2003-08-08 2009-09-09 诺瓦提斯公司 包含星孢素的组合
US7691861B2 (en) * 2004-01-19 2010-04-06 Novartis Ag Indolymaleimide derivatives
WO2005097108A1 (fr) * 2004-04-08 2005-10-20 Novartis Ag Inhibiteurs de proteine kinase c destines au traitement de maladies auto-immunes et de rejets de transplantation
EP1765313A2 (fr) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Composes utilises pour l'immunopotentialisation
EP1819697B1 (fr) * 2004-12-08 2012-08-01 Johannes Gutenberg-Universität Mainz Derives de 3-(indolyl)-4-arylmaleimide et utilisation comme inhibiteurs de l'angiogenese
KR20070103009A (ko) * 2005-01-04 2007-10-22 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 뇌혈류를 증가시키는 방법
CN101941970B (zh) 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
JP2009501172A (ja) * 2005-07-11 2009-01-15 ノバルティス アクチエンゲゼルシャフト インドリルマレイミド誘導体
US20070066526A1 (en) * 2005-09-02 2007-03-22 Daria Mochly-Rosen Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US20070112053A1 (en) 2005-09-16 2007-05-17 Pickett Cecil B Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
EP2125683B1 (fr) * 2006-12-19 2013-10-23 The Board of Trustees of the University of Illinois 3-benzofuranyl-4-indolyl-maléimides en tant qu'inhibiteurs de gsk-3 puissants pour troubles neurodégéneratifs
CA2690782C (fr) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions et procedes de traitement du cancer
WO2009002806A1 (fr) * 2007-06-22 2008-12-31 Arqule, Inc. Dérivés de pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine et thiosuccinimide, compositions et procédés pour le traitement d'un cancer
JP2010530885A (ja) * 2007-06-22 2010-09-16 アークル インコーポレイテッド キナゾリノン化合物およびその使用方法
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
US8304421B2 (en) * 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
EP2338486A1 (fr) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz Dérivés de 3-(indolyl)- ou de 3-(azaindolyl)-4-arylmaléimide pour usage dans le traitement de l'adenocarcinome du colon et de l'estomac
EP2343291A1 (fr) * 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz Composés de 3-(indolyl)- ou 3-(azaindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
EP2474541A1 (fr) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Composés conjugués de 3-(indolyl)- et 3-(azaindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
US9993463B2 (en) * 2012-12-10 2018-06-12 Centogene Ag Use of maleimide derivatives for preventing and treating cancer
US9724331B2 (en) 2012-12-10 2017-08-08 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
CN103382199A (zh) * 2013-06-28 2013-11-06 北京理工大学 一种n-烷基-双吲哚马来酰亚胺的制备方法
EP3741375A1 (fr) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de maladies associées aux jonctions neuromusculaires
WO2016207366A1 (fr) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement d'infections virales
EP3187495A1 (fr) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz Composés de 3-(5-fluoroindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
CN109535158B (zh) * 2016-04-26 2021-04-23 浙江工业大学 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
CA2015996C (fr) * 1989-05-05 2001-08-28 Hartmut Osswald Derives de bis-(1h-indole-3-yl)-maleinimide et leur utilisation comme produits pharmaceutiques

Also Published As

Publication number Publication date
NO172540C (no) 1993-08-04
FI890652A (fi) 1989-08-11
HUT49348A (en) 1989-09-28
YU28489A (en) 1991-06-30
NZ227850A (en) 1991-11-26
HU201054B (en) 1990-09-28
EP0328026B1 (fr) 1993-04-28
AU623630B2 (en) 1992-05-21
CZ75289A3 (en) 1995-12-13
IS3433A7 (is) 1989-08-11
PH25185A (en) 1991-03-27
JPH0730071B2 (ja) 1995-04-05
IS1941B (is) 2004-07-30
NO890568L (no) 1989-08-11
IE890416L (en) 1989-08-10
PT89661A (pt) 1989-10-04
PT89661B (pt) 1994-02-28
NO172540B (no) 1993-04-26
FI96861C (fi) 1996-09-10
FI890652A0 (fi) 1989-02-10
FI96861B (fi) 1996-05-31
AU2965889A (en) 1989-08-10
IL89167A (en) 1994-02-27
CA1320194C (fr) 1993-07-13
JPH01233281A (ja) 1989-09-19
US5057614A (en) 1991-10-15
DE58904168D1 (de) 1993-06-03
SK75289A3 (en) 1998-05-06
SK278989B6 (sk) 1998-05-06
ES2054890T3 (es) 1994-08-16
IL89167A0 (en) 1989-09-10
EP0328026A1 (fr) 1989-08-16
DZ1323A1 (fr) 2004-09-13
CZ280738B6 (cs) 1996-04-17
IE63489B1 (en) 1995-05-03
NO890568D0 (no) 1989-02-09
DK171891B1 (da) 1997-08-04
DK55889D0 (da) 1989-02-07
DK55889A (da) 1989-08-11
YU47101B (sh) 1994-12-28

Similar Documents

Publication Publication Date Title
MC2010A1 (fr) Pyrroles substitues
ES2012750A4 (es) Conjunto recipiente-aplicador
ATA901789A (de) Somatostatinpeptid
BR8806093A (pt) Trepano
ATA900689A (de) Calcitoninpeptide
ATA172889A (de) Furanderivate
DE68926597D1 (de) Mikrorechner
BR8902098A (pt) Eletrolisador
DK578389D0 (da) Substituerede oxadiaminobutaner
DK113291A (da) Homogent enzymimmunassay
BR8906898A (pt) Jamela
DK119691D0 (da) Loeftesele
DK429689A (da) Substituerede pyridazinoner
DE68926367T2 (de) Hydroxymethylcyclobutylpurine
DD277186A3 (de) Waelzlagerseparator
IT8822158A0 (it) Pirroli disostituiti.
FI88436C (fi) Foerfarande foer maetning av en vaegs laengdprofil
TR23770A (tr) Jarjoerlue otomotik av tuefegi
BR8804416A (pt) Papa-mosca
BR6800020U (pt) Flutuador-leme
BR8803070A (pt) Rende-lapis
BR8907290A (pt) Diisopropilbenzeno-bis-peneoalcanoatos
BR8801701A (pt) Anti-ivh
DK137688D0 (da) Gaffelloeftevogn
BR8806404A (pt) Multiregua

Legal Events

Date Code Title Description
YP Annual fee paid